Clinical Trial Update: MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) [Phase 3]

View source ↗

Summary

A Phase 3 factorial trial evaluated the safety and glucose-lowering effects of co-administering MK0431 with pioglitazone in adults with Type 2 Diabetes Mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK0431
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2011-10-17